Netupitant PET imaging and ADME studies in humans. - Wikidata - wikimedia - TriplyDB

Netupitant PET imaging and ADME studies in humans.

Netupitant PET imaging and ADME studies in humans.

http://www.wikidata.org/entity/Q34377521

about

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Netupitant/Palonosetron.Netupitant, a Potent and Highly Selective NK1 Receptor Antagonist, Alleviates Acetic Acid-Induced Bladder Overactivity in Anesthetized Guinea-Pigs Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Newest Drugs for Chronic Unexplained Nausea and Vomiting.Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers.Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 study.Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework

P2860

Q26748524-8949B5C9-1485-4323-BF47-BEF7D947B9BC Q26784064-565FC381-BE3D-49C7-BB9D-0F767405121A Q33809595-F0DF3BC4-708F-438F-9837-A74B64B84D3D Q34011870-304F1C5F-3F28-4E5C-9C5F-97DEE2162208 Q34775395-68E2840D-F49A-48EA-BEEA-364E96715D08 Q36110050-AEAC818C-AB4F-4926-B776-AEDFB1A76060 Q37150382-E99FC4C4-CEFE-4486-A974-EADDBDF5C6BA Q37669043-599DCF5F-20A8-40CA-8781-D734369AE541 Q38264147-2D820D35-FD09-4FA9-8577-4415397E94CD Q38443441-4A821007-0517-4367-9965-BCE90FED7E3F Q38650400-663B92F5-39D1-454A-A1D9-5CADB48E4DEA Q38677762-666C9516-5F1D-40E5-BA94-16A005738288 Q38977503-52DE6260-C7F2-4F94-9663-CE0CF1B588BB Q39275766-07099B24-D273-4E32-B591-FCC806356335 Q40542547-E46B89B4-D4F6-4EAE-A228-538D394327DF Q41386264-9122E6BF-6F49-45B7-9CE7-B2E60A811C33 Q48331868-9DA1E199-FBE8-422B-957C-6111D2285FBA Q51285173-9E9A05BC-B906-44C4-9499-82E67DA39B98 Q57483947-96EAECAD-7965-4BD8-B912-C328C2C12E9E Q58788199-B183A1C3-603B-4B27-B7C2-91B54F67620B

P2860

Netupitant PET imaging and ADME studies in humans.

http://www.wikidata.org/entity/Q34377521

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Netupitant PET imaging and ADME studies in humans.

@ast

Netupitant PET imaging and ADME studies in humans.

@en

Netupitant PET imaging and ADME studies in humans.

@nl

type

label

Netupitant PET imaging and ADME studies in humans.

@ast

Netupitant PET imaging and ADME studies in humans.

@en

Netupitant PET imaging and ADME studies in humans.

@nl

prefLabel

Netupitant PET imaging and ADME studies in humans.

@ast

Netupitant PET imaging and ADME studies in humans.

@en

Netupitant PET imaging and ADME studies in humans.

@nl

P1433

Q34377521-70288FDC-D5BD-46A9-B344-5D966060BE22

P1476

Q34377521-B6A49B5B-8C0D-4F62-A4B0-469B94034AE2

P2093

Q34377521-00C0F732-2CEE-4DE3-A97F-EE0FCBFB2EB7

Q34377521-2A3DF892-B94B-4494-A7B7-93A4CA0F1082

Q34377521-4FF8E666-CB4B-4C0B-93EA-47D0695EFFCE

Q34377521-70750415-DFE7-40B1-8BE7-AA97825AC47F

Q34377521-AD66E0F4-910A-4EFA-9296-90AE799A417E

Q34377521-B54891D6-0DCF-4032-B0AB-23CACF321FB1

Q34377521-BBB61AAE-AC7B-4397-B868-839A3172C9DD

Q34377521-EF7D5F99-D5D1-497B-B71F-64E7946EBBD1

P2860

Q34377521-0A0B2D72-86FA-46BD-8DCE-28B600FCFEDB

Q34377521-0E179745-A659-4DCD-A79B-6603E48BCB3D

Q34377521-0F19B9CC-BBA8-4832-B67E-BD02028CFAAE

Q34377521-14FFE4C6-D950-42AF-BF10-83D576953484

Q34377521-16B8A3DE-4CEE-47B0-89A0-4D58F2CA992B

Q34377521-16E2C598-B9D7-4B80-940A-515609E0B3E6

Q34377521-195F2AEE-0B3C-4E6F-AA35-A16526114D46

Q34377521-22CF3AEB-89E4-44E7-B5A4-D7A6792C5DA7

Q34377521-28E0848F-8BC6-47D0-AFEF-D258D62D991C

Q34377521-2ED33EE4-F64C-4AA4-8F5A-B762016E987C

P304

Q34377521-06824AC3-7276-43A1-978D-6CB7BC57BEF2

P31

Q34377521-5B779002-9202-4343-B920-BE3388497324

P356

Q34377521-ED02F99B-8DCF-4D78-B85C-7CDA2F4E5638

P433

Q34377521-2AE95641-95D2-4A29-B990-0390951C7901

P478

Q34377521-37521BC5-6EE4-4256-8491-48D88C2AE23A

P577

Q34377521-2E3DC510-FA95-4D66-A433-456268B89084

P5875

Q34377521-4291D9B4-7CB2-48B1-8D44-ADC668A09C5E

P698

Q34377521-07975765-5D55-4DCD-A190-911DFD4873E7

P921

Q34377521-A68638F5-C0FD-41E2-854D-BA5D23FEEDEF

P932

Q34377521-D6A4FB6B-ED40-4ACC-899E-FA77F14C8ACB

P356

P1433

The Journal of Clinical Pharmacology

P1476

Netupitant PET imaging and ADME studies in humans.

@en

P2093

Claudio Giuliano

http://www.w3.org/2001/XMLSchema#string

Corinna Lanzarotti

http://www.w3.org/2001/XMLSchema#string

Giorgia Rossi

http://www.w3.org/2001/XMLSchema#string

Ian Nisbet

http://www.w3.org/2001/XMLSchema#string

Lloyd Stevens

http://www.w3.org/2001/XMLSchema#string

Selma Calcagnile

http://www.w3.org/2001/XMLSchema#string

Stuart Mair

http://www.w3.org/2001/XMLSchema#string

Tulla Spinelli

http://www.w3.org/2001/XMLSchema#string

P2860

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Update and new trends in antiemetic therapy: the continuing need for novel therapies.

A pharmacokinetic PET study of NK₁ receptor occupancy.

In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.

P304

97-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.198

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257755585

http://www.w3.org/2001/XMLSchema#string

P698

24122871

http://www.w3.org/2001/XMLSchema#string

P921

P932

4282341

http://www.w3.org/2001/XMLSchema#string